Table 2.

Results of prospective randomized trials

Country	Author	Ref	Trial name	Year	Conclusions
Use in respiratory infections
Switzerland	Christ-Crain	[20]	None	2006	PCT level prevented initial antibx use, earlier discontinuation antibx, less overall use
Switzerland	Briel	[23]	None	2008	PCT level prevented initial antibx use, decreased overall antibx exposure and duration
Swiss/USA	Stolz	[25]	None	2009	PCT level allowed earlier discontinuation antibx, decreased total exposure and duration
Switzerland	Schuetz	[26]	ProHosp	2009	adverse outcomes similar, PCT group had fewer adverse events, less total antibx use
Use in sepsis
Switzerland	Nobre	[21]	None	2008	PCT allowed earlier discontinuation of antibx, decreased overall antibx exposure
Germany	Schroeder	[22]	None	2008	PCT allowed earlier discontinuation of antibx, cost of antibx reduced
Use in sepsis in the ICU setting
Germany	Hochreiter	[24]	None	2009	PCT allowed earlier discontinuation of antibx, shorter ICU length of stay
France	Bouadma	[27]	PRORATA	2010	PCT allowed earlier discontinuation of antibx, decreased overall antibx exposure
Netherlands	De Jong	[28]	SAPS	2013	No longer recruiting patients, results pending
Australia	Shehabi	[30]	ProGuard	2014	PCT group had 2 less days of antibx but not statistically significant

Ref references, PCT procalcitonin, antibx antibiotics